Boston Scientific Just Took A 9% Header. Why Analysts Are Still Bullish.

robot
Abstract generation in progress

Boston Scientific’s stock (BSX) plummeted 9% to a two-year low after mixed test results for its Watchman FLX device, which prevents strokes. Despite the significant drop, analysts remain bullish on the medical device company, indicating confidence in the product’s long-term potential or other aspects of the business. The Watchman FLX is a minimally invasive device designed to seal off the heart’s left atrial appendage, where most blood clots form.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin